Biogen Idec, Inc. - SWOT Analysis

Datamonitor's Biogen Idec, Inc. *SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the companys key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Biogen Idec is a biopharmaceutical company engaged in the development, manufacturing, and commercialization of novel therapies in the areas of oncology, neurology, immunology and cardiology. The company's key products include Avonex and Rituxan. The company primarily operates in the US and Europe. The company is headquartered in Cambridge, Massachusetts and employs 4,300 people. The company recorded revenues of $3,171.6 million during the financial year (FY) ended December 2007, an increase of 18.2% over 2006. The operating profit of the company was $779.8 million during FY2007, as compared to an operating profilt of $440 million in 2006. The net profit was $638.2 million in FY2007, as compared to a net profit of $217.5 million in 2006.

Scope of the Report

• Provides all the crucial company information required for business and competitor intelligence needs
• Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
• Data is supplemented with details on the companys history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement

Reasons to Purchase

• Support sales activities by understanding your customers businesses better

*Qualify prospective partners and suppliers

• Keep fully up to date on your competitors business structure, strategy and prospects
• Obtain the most up to date company information available